Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Cucurbitacin D** is a highly oxygenated tetracyclic triterpenoid natural product found in plants such as Cucurbita texana and Ecballium elaterium. It exerts potent **anti-cancer and pro-apoptotic activity** in a range of cancer cell models, including cervical, breast, and colorectal cancers[1][4][7][16]. Its mechanism of action includes the disruption of Hsp90 (heat shock protein 90) and co-chaperone (Cdc37 and p23) interactions, leading to impaired maturation of Hsp90-dependent client proteins (such as Her2, Raf, Cdk6, and pAkt)[2][15]; inhibition of the PI3K-Akt, JAK-STAT, and ErbB signaling pathways; reduction of phosphorylated STAT3, Akt, and NF-κB signaling; induction of apoptosis via effects on PARP cleavage, p53, Bcl-2, and caspase-3; and cell cycle arrest at the G1/S phase through downregulation of Cyclin D1 and CDK4 and upregulation of p21 and p27[1][4][7][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cucurbitacin D.